We’re making an even greater impact against viral diseases and breaking new ground in cancer and inflammation to help build a healthier world for all.
Our Therapeutic Leadership
For more than 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well managed, and we’ve helped cure millions of people with hepatitis C around the world. Our decades of research in emerging viruses allowed us to deliver the first approved treatment for COVID-19. And together with Kite, a Gilead Company, which is focused on cell therapy, we’re helping to make an impact in multiple types of cancer.
Known for our commitment to innovation and access, we are poised to meet our ambition, set in 2019, to deliver 10+ transformative therapies by 2030.
Leading and Innovating in Virology
- What We’ve Accomplished
- Our Current Focus
- Looking Ahead
What We’ve Accomplished
As a leader and pioneer in antiviral development, we helped transform HIV from a fatal illness to a preventable chronic condition. We introduced the first HIV single tablet treatment regimen and continue to improve safety, convenience and efficacy in treatment and prevention options. In hepatitis, we developed a cure for hepatitis C, and our therapies helped transform hepatitis B into a more manageable condition. And when the world needed us, we stepped up to deliver the first approved antiviral medicine to treat COVID-19.
These advances were possible thanks to our investment in world-class science, our deep connections with community partners and our long-standing commitment to expanding health equity.
Our Current Focus
Looking Ahead
Our work in Oncology
- Innovation
- Impact
Innovation
We’re innovating with next-generation therapies, combinations and technologies to expand our oncology portfolio. Gilead and Kite are continuing to expand our oncology platform across major pathways, including cell therapies and medicines for difficult-to-treat metastatic cancers.
We’re actively collaborating with the oncology community in pursuit of equitable access to cancer care.
Impact
Innovating to Advance Care for Inflammatory Disease
- Pursuing Next-Generation Therapies
- Leveraging Our Expertise
Pursuing Next-Generation Therapies
Effective therapies are needed to treat inflammatory and fibrotic diseases. Even with recent advances, many people still have few treatment options and continue to experience symptoms and disease progression.
We believe long-term remission, or in some cases, a cure, might be possible for many of these diseases despite the challenges they present. We’re leveraging our past successes and learnings and applying them to our research today — with the hope of bringing effective therapies to as many people as possible.